Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nuevolution, a drug discovery company, has announced that Merck & Co has chosen to proceed to the second phase of the collaboration agreement announced in June 2008 to apply Nuevolution's Chemetics drug discovery technology to identify novel small molecule leads against several drug targets.
Subscribe to our email newsletter
By entering the second phase, Merck gains access to a new multi-million member library of small molecule drug candidates. In addition, this development triggers the payment of an undisclosed technology access fee to Nuevolution from Merck.
Alex Gouliaev, CEO of Nuevolution, said: “We are pleased with Merck’s decision to proceed with the collaboration into its second phase. We look forward to decoding the active structures arising from this proprietary library.”